KPTI News and Press, Karyopharm Therapeutics Inc. From 08/21/23

2023-08-21 03:07:26 ET Summary Karyopharm Therapeutics reported $37.6 million in total revenue, with a net loss of $32.6 million. The company holds $80.9 million in cash and equivalents, as well as $156 million in investments. KPTI has a commercialized drug and potential for g...

2023-08-03 10:48:49 ET In a stock market characterized by growing unpredictability, traders are leaning on every possible resource. One such indispensable tool, whether dealing with penny stocks or more expensive shares, is the insight provided by analysts. This expertise can shed l...

2023-08-02 14:55:22 ET Karyopharm Therapeutics Inc. (KPTI) Q2 2023 Earnings Conference Call August 2, 2023 08:00 ET Company Participants Elhan Webb - Senior Vice President, Investor Relations Richard Paulson - President and Chief Executive Officer Reshma Rangwala...

2023-08-02 14:00:24 ET Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q2 2023 Earnings Call Aug 02, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q2 2023 Earni...

2023-08-02 07:43:12 ET Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q2 GAAP EPS of -$0.29 beats by $0.06 . Revenue of $37.6M (-5.2% Y/Y) beats by $1.93M . Net product revenue: Net product revenue for the second quarter of 2023 was $28.5 million, co...

Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – ...

2023-08-01 13:18:22 ET Karyopharm Therapeutics ( NASDAQ: KPTI ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is -$0.34 (vs. -$0.62 last year) and the consensus Revenue Estimate is $35.67M (-10.1% Y/Y)...

Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023 PR Newswire -- Conference Call Scheduled for Wednesday, August 2, 2023 , at 8:00 a.m. ET -- NEWTON, Mass. , July 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Na...

Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer PR Newswire Signal of PFS Improvement in SIENDO for Selinexor-Treated Patients was Observed Only in Subgroup Wh...

Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25th PR Newswire - Data Provide Further Support for Company's Ongoing Phase 3 St...